Vanguard Capital Management
LUCD icon

Vanguard Capital Management’s Lucid Diagnostics LUCD Stock Holding History

Vanguard Capital Management’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.54M Sell
6,045,227
-511,117
-8% -$478K ﹤0.01% 3114
2026
Q2 		$7.02M Buy
6,556,344
+2,401,574
+58% +$2.59M ﹤0.01% 2989
2026
Q1 		$4.78M Buy
+4,154,770
New +$5.29M ﹤0.01% 3080

Other funds holding LUCD

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Perkins Capital Management
Perkins Capital Management Wayzata, Minnesota $140M AUM 109.55% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return

Vanguard Capital Management's LUCD Position: Q3 2026 in Review

Vanguard Capital Management reduced its Lucid Diagnostics (LUCD) stake by 7.8% in Q3 2026, selling an estimated $478K and leaving 6,045,227 shares worth $4.54M. The position accounts for ﹤0.01% of the portfolio, ranked #3114.

Vanguard Capital Management first reported a position in LUCD in Q1 2026 and has held it in 3 quarters since. The position peaked at $7.02M in Q2 2026. 82 funds tracked by Wall St. Rank hold LUCD as of Q3 2026.

  • Vanguard Capital Management held 6,045,227 shares of Lucid Diagnostics worth $4.54M as of Q3 2026.
  • Vanguard Capital Management sold 511,117 Lucid Diagnostics shares in Q3 2026, an estimated $478K.
  • Lucid Diagnostics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3114 holding.
  • Vanguard Capital Management first reported a position in Lucid Diagnostics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Lucid Diagnostics position peaked at $7.02M in Q2 2026.
  • 82 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.